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Women and Ischemic Heart Disease
Paradox and Pathophysiology*
C. Noel Bairey Merz, MD
Los Angeles, CaliforniaIn the U.S., more than a quarter of a million women
die each year from ischemic heart disease (IHD),
and current projections indicate that this will in-
crease with our aging population and epidemics of
obesity, metabolic syndrome, and diabetes mellitus.
Notably, IHD is the leading killer of women at all
ages, with annual mortality rates affecting greater
numbers of younger and older women than breast
See page 65
cancer. Furthermore, resource consumption pat-
terns in women are characterized by more frequent
angina diagnosis, more office visits, more avoidable
hospitalizations, higher myocardial infarction (MI)
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Medtronic and Johnson and Johnson.mortality, and higher rates of heart failure as com-
pared with men (1). Clear sex differences in the
presentation, pathophysiology, and treatment of
IHD underscore the need for more study of
women.
Three paradoxes are evident with regard to sex
differences in IHD (2). First, women have a higher
prevalence of angina compared to men, yet have an
overall lower prevalence of atherosclerosis and ob-
structive coronary artery disease (CAD). Second,
symptomatic women undergoing coronary angiog-
raphy have less extensive and severe CAD, despite
being older with a greater risk factor burden,
compared to men. Third, despite relatively less
CAD, women have a more adverse prognosis com-
pared to men. These 3 paradoxical findings suggest
an alternative, sex-specific pathophysiology for
IHD in women, given our traditional understand-
ing that the majority of angina and adverse cardio-
vascular outcomes stem from obstructive CAD.
Advanced cardiac imaging can be used to further
our understanding of the pathophysiology of these
paradoxes of ischemic heart disease in women
(Fig. 1). Identification of nonobstructive atheroma
is increasingly important and can be visualized and
quantified now by intravascular coronary ultra-
sonography, coronary artery calcium (CAC) score,
and computed tomography angiography, the latter
2 using fast computed tomography scanning. The
gold standard identification for microvascular cor-
onary dysfunction (MCD) which is a common
concomitant of nonobstructive atherosclerosis, is
invasive coronary reactivity testing for measurement
of both endothelial- and nonendothelial-dependent
reactivity (3). Additional advanced imaging modal-
ities that show promise for the noninvasive assess-
ment of this include magnetic resonance (MR)
angiography of the coronary artery and transtho-
racic echocardiography Doppler coronary artery
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75ow, both in response to pharmacological stressors.
inally, assessment of the nonsegmental myocardial
erfusion abnormalities associated with MCD can
e measured by cardiac MR perfusion imaging, and
bsolute myocardial blood flow reserve by positron
mission tomography. Identification of nonobstruc-
ive CAD (4), MCD (5), and abnormal nonseg-
ental perfusion abnormalities (6) are associated
ith an elevated risk of adverse events similar to
bstructive CAD. Cardiac MR perfusion imaging
s uniquely able to visualize epicardial versus sub-
ndocardial myocardium; prior work has provided
vidence of subendocardial perfusion abnormalities
n women with signs and symptoms of ischemia but
o obstructive CAD (7). The National Heart,
ung, and Blood Institute-sponsored WISE
Women’s Ischemia Study Evaluation) study has
dditionally documented the presence of myocardial
schemia in these patients using cardiac MR spec-
roscopy (8). Because of the relatively high fre-
uency of MCD in symptomatic women with and
ithout CAD (9,10), this constellation of findings
uggests that MCD plays a central role in the
enesis of symptoms and ischemia, and may be a
lobal estimator of outcome in female IHD patho-
hysiology, as outlined in Figure 1 (11).
The current findings published from the Dallas
eart Study by Banks et al. (12) provide additional
ovel data that further support this unfolding un-
erstanding of an alternative sex-specific patho-
Figure 1. Advanced Imaging Modalities to Detect Abnormalities
Adapted, with permission, from Shaw et al. (11). HTN  hypertensio
QCA  quantitative coronary angiography; Sept  septal.hysiology for IHD in women. Using the advanced aardiac imaging technique of CAC, these investi-
ators found, in a relatively large community-based
opulation that oversampled with African Ameri-
ans, that angina was not related to atherosclerosis
easured by CAC, but was related to novel risk
actors, including central obesity, insulin resistance,
erum inflammatory markers, and reduced aortic
ompliance. The Dallas Heart study used robust
ethods of subject sampling, standardized defini-
ions, and core laboratory measures, and so provides
good estimate of angina, atherosclerosis, and
ther marker prevalence in women. While noncal-
ified atherosclerosis can be present in women and
ounger adults, the confirmatory MR imaging-
easured aortic atherosclerosis findings are reassur-
ng that this did not likely confound the results.
What can we learn from this new work regarding
he 3 paradoxes of IHD in women? Among the
omen in the Dallas Heart study with angina
nd/or CAC (n  318) (Table 1) (12), the largest
ubgroup (64%) had atherosclerosis without angina,
onsistent with our understanding of the relatively
arge burden of asymptomatic atherosclerosis
mong women in the community (1). The preva-
ence of symptomatic atherosclerosis was the lowest
7%) subgroup, supportive of the finding that a
ajority of women with CAD do not have classic
ngina symptoms (2), which contributes to under-
iagnosis or misdiagnosis in women. Notably, the
econd most prevalent subgroup was women with
Microvascular Angina
NF  inferior; LAT  lateral; PCOS  polycystic ovary syndrome;of
n; Ingina in the absence of atherosclerosis (29%)—
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76onsistent with the accumulated literature docu-
enting that as many as one-third of women have
igns and symptoms of myocardial ischemia with-
ut evident CAD (13). While there are 6 million
omen in the U.S. with clinically documented
AD, we have estimated the prevalence of signs
nd symptoms of IHD in the absence of CAD
sing the National Cardiovascular Data Registry
atabase to be 2 to 3 million women (1), again
onsistent with these new community population
ata.
Notably, the investigators document that,
hereas the presence of atherosclerosis measured by
AC was associated with traditional risk factors,
ngina without CAC was not, and had a paradox-
cally greater clustering of more novel risk factors
ncluding central obesity, insulin resistance, vascular
nflammation, and aortic compliance. Although
ultivariate analyses identified only African-
merican ethnicity, family history of myocardial
nfarction, and central obesity as independent risk
actors, the risk factor clustering captured by the
ational Cholesterol Program Adult Treatment
anel 3 term “metabolic syndrome” is known to be
convenient clustering of traditional and novel risk
actors that are difficult to separate. This pattern of
isk-clustering data supports the WISE study hy-
otheses outlined in figure 1 (11), suggesting a
athophysiological link between angina and
onatherosclerotic-mediated vascular reactivity.
Regrettably, but by design, the current study did
ot include either measures of endothelial, nonen-
othelial, or myocardial perfusion reserve testing.
e, therefore, cannot add specifically to our knowl-
dge regarding the second paradox listed, and
hether endothelial, nonendothelial, or both vascu-
ar reactivity pathophysiological pathways contribute
o myocardial ischemia and thereby angina in women
ith a relatively lesser extent and severity of angio-
raphic CAD. The WISE study data, which evalu-
ted higher risk, symptomatic subjects, documented a
igh prevalence of atherosclerosis by intravascular
oronary ultrasonography in women associated with
CD—additional community data using advanced
maging are needed to confirm whether this relation
olds true or whether they are unrelated to each other.
lthough the vascular inflammatory markers mea-
ured (soluble intracellular adhesion molecule-1, sol-
ble vascular cell adhesion molecule) have been cor-
elated with endothelial dysfunction, as cited by the
allas Heart investigators, prior WISE study workailed to demonstrate links to vascular reactivity in romen. The coronary flow reserve did not correlate
ith levels of high-sensitivity C-reactive protein,
nterleukin-6, interleukin-18, tumor necrosis factor-,
ransforming growth factor-1, and soluble intracel-
ular adhesion molecule-1 (14), although serum amy-
oid high-sensitivity C-reactive protein was a strong
redictor of adverse cardiac events (15,16). These
ombined data suggest the hypothesis that vascular
nflammation may promote endothelial dysfunction
nd atherosclerotic plaque destabilization, but poten-
ially not nonendothelial smooth muscle pathophysi-
logical pathways in women. More work is needed.
And what about the third and final paradox?
hy do women have more adverse outcomes de-
pite less extensive CAD and better ventricular
unction? The literature suggests that when women
ook like men (with typical symptoms and obstruc-
ive CAD), they are more likely to be treated like
en and benefit from aggressive interventional and
edical therapies. As characterized by the “Yentl”
yndrome depicted in the Barbra Streisand movie of
he same name, Healy (17) used this term to call
ttention to the paradox of adverse outcomes of
omen with IHD in preparation for the National
nstitutes of Health Women’s Health Initiative.
his literature documents that interventional strat-
gies are equally effective in biomarker positive
omen and men in the setting of obstructive
AD (11).
But what do these new data tell us about the
ne-third of women with signs and symptoms of
schemic but no obstructive CAD? These new
allas Heart Study data combined with prior work
uggests that this sizable group contributes to the
dverse morbidity and mortality experienced by
omen in part related to MCD. Because MCD is
aradoxically poorly predicted by traditional cardio-
ascular disease risk factors (10), the current diag-
osis is challenging to physicians, and knowledge
egarding potential preventive or treatment strate-
ies lacks an evidence base. The current strategy,
hich aims to detect obstructive coronary stenosis,
s less effective in women with a greater prevalence
f signs and symptoms of ischemia unrelated to
bstructive CAD. Alternative strategies using tools
o detect the “vulnerable patient” should be more
seful and may be preferentially helpful in women.
ovel imaging strategies aimed at pathophysiolog-
cal pathways, including measures of nonendothe-
ial, endothelial function, vascular and myocardial
ompliance, as well as myocardial perfusion and
ow reserve are actively being investigated as useful
isk markers and diagnostic strategies. Noninvasive,
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77onionizing radiation strategies are needed for this
urpose, as invasive study has documented the
easibility of identifying future risk by pathophysi-
logical evaluation in women with no obstructive
AD (18). Further closure of knowledge gaps
elated to the paradox and the pathophysiology ofColl Cardiol 2010;55:2825–32. al. Clinical characmprove the health of the 51% of the population
hat is female.
eprint requests and correspondence: Dr. C. Noel Bairey
erz, Cedars-Sinai Heart Institute, 444 South San
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